Steven Knapper

18PUBLICATIONS
95CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

|May 03, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

|Nov 14, 2025
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Steven Knapper, Laura W Dillon, Malavika Babu

|Sep 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Nigel Russell, Jad Othman, Oliver Cumming

|May 22, 2025
A revised prognostic model for patients with acute myeloid leukemia and first relapse.

Niek G van der Maas, Dimitri Breems, Clara P W Klerk

|Nov 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Nigel H Russell, Abin Thomas, Robert K Hills

Pageof 3

Frequent Collaborators

11 joint publications

Sylvie Freeman

7 joint publications

Abin Thomas

6 joint publications

Priyanka Mehta

6 joint publications

Mary Frances McMullin